Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (abbreviated):~1. Women ≥18 years~2. Women with ectocervical HPV16+ associated High Grade Cervical Intraepithelial Neoplasia (HSIL) as verified by local pathology:~   (Dosing Phase: Women with histologically confirmed HPV16+ associated CIN 2; Expansion Phase: Women with histologically confirmed HPV16+ associated CIN 2/3)~3. Satisfactory colposcopic examination.~Exclusion Criteria (abbreviated):~1. More than 2 cervical quadrants of CIN 3 as visualised by colposcopy.~2. Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease.~3. Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination.~4. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV).~5. Administration of any blood product within 3 months of enrolment.~6. Concomitant or prior malignant disease.~7. Clinically significant autoimmune disease.~8. Known allergy to Kanamycin or other aminoglycosides~9. Known immunodeficiency and or immunosuppression.~10. History of toxic shock syndrome.~11. Evidence or history of clinically significant cardiac disease~12. Active infection requiring parenteral antibiotics.~13. Tattoos, scars, or active lesions/rashes within 2 cm of the site of vaccination or any implantable leads.~14. Immunosuppression~15. Major surgery within 3 months of trial entry.~16. Current or recent (within 30 days of first study treatment) participation in a clinical trial.~17. Previous vaccination (either therapeutic and/or prophylactic) against HPV.~18. Administration of any live vaccine within 90 days of trial entry.~19. Concomitant anticancer therapies.~20. Inadequate bone marrow function~21. Inadequate liver function~22. Clinical significant electrolyte abnormalities~23. Women of childbearing age not willing to use an effective form of contraception~24. Pregnancy or intention to become pregnant~25. Nursing women~26. Evidence of any other medical condition that may interfere with study participation, patient compliance or place the patient at high risk from treatment-related complications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: 3mg VB10.16 Vaccine (Type: EXPERIMENTAL): VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
- Cohort 2: 3mg VB10.16 Vaccine (Type: EXPERIMENTAL): VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).